InsiderTrades.com logo
Watch this before it gets removed
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
Stephen George Dilly net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Stephen Dilly Biography and Net Worth

CEO of Sierra Oncology
Stephen G. Dilly, MBBS, PhD, has served as our President and Chief Executive Officer and as a member of our Board of Directors since June 2020. Previously, Dr. Stephen Dilly brings three decades of executive management experience in the biopharmaceutical industry. Most recently, Dr. Dilly served as CEO and Board Member of Aimmune Therapeutics. Dr. Dilly has served in executive roles at Genentech, Chiron and SmithKline Beecham and has been associated with the development and launch of many marketed drugs across multiple therapeutic areas. Dr. Dilly also currently serves on the Board of Directors of one public biotechnology company and several private companies. He holds an MBBS from the University of London and a PhD in Cardiac Physiology from University of London.

What is Stephen George Dilly's net worth?

The estimated net worth of Stephen George Dilly is at least $22.40 million as of March 7th, 2023. Dr. Dilly owns 407,386 shares of Sierra Oncology stock worth more than $22,402,156 as of November 23rd. This net worth evaluation does not reflect any other investments that Dr. Dilly may own. Additionally, Dr. Dilly receives a salary of $1,020,000.00 as CEO at Sierra Oncology. Learn More about Stephen George Dilly's net worth.

How old is Stephen George Dilly?

Dr. Dilly is currently 62 years old. There are 5 older executives and no younger executives at Sierra Oncology. Learn More on Stephen George Dilly's age.

What is Stephen George Dilly's salary?

As the CEO of Sierra Oncology, Inc., Dr. Dilly earns $1,020,000.00 per year. Learn More on Stephen George Dilly's salary.

How do I contact Stephen George Dilly?

The corporate mailing address for Dr. Dilly and other Sierra Oncology executives is 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. Sierra Oncology can also be reached via phone at (604) 558-6536 and via email at [email protected]. Learn More on Stephen George Dilly's contact information.

Has Stephen George Dilly been buying or selling shares of Sierra Oncology?

Stephen George Dilly has not been actively trading shares of Sierra Oncology in the last ninety days. Most recently, on Wednesday, May 19th, Stephen George Dilly bought 5,000 shares of Sierra Oncology stock. The stock was acquired at an average cost of $17.83 per share, with a total value of $89,150.00. Following the completion of the transaction, the chief executive officer now directly owns 5,000 shares of the company's stock, valued at $89,150. Learn More on Stephen George Dilly's trading history.

Who are Sierra Oncology's active insiders?

Sierra Oncology's insider roster includes Gaurav Aggarwal (Director), Craig Collard (Director), Stephen Dilly (CEO), Mary Thomson (General Counsel), and William Turner (Insider). Learn More on Sierra Oncology's active insiders.

Stephen George Dilly Insider Trading History at Sierra Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/19/2021Buy5,000$17.83$89,150.005,000View SEC Filing Icon  
See Full Table

Stephen George Dilly Buying and Selling Activity at Sierra Oncology

This chart shows Stephen George Dilly's buying and selling at Sierra Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sierra Oncology Company Overview

Sierra Oncology logo
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $54.99
Low: $54.99
High: $54.99

50 Day Range

MA: $54.93
Low: $54.73
High: $54.99

2 Week Range

Now: $54.99
Low: $14.91
High: $55.19

Volume

N/A

Average Volume

931,731 shs

Market Capitalization

$1.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03
Watch this before it gets removed
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.